296 related articles for article (PubMed ID: 26404644)
1. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
Lin YL; Gui SL; Guo H; Ma JG; Li WP
Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
[TBL] [Abstract][Full Text] [Related]
2. Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma.
Lin YL; Wang YP; Li HZ; Zhang X
Med Sci Monit; 2017 Jul; 23():3318-3323. PubMed ID: 28688232
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma.
Lin YL; Wang YL; Fu XL; Ma JG
Med Sci Monit; 2014 Nov; 20():2380-5. PubMed ID: 25416427
[TBL] [Abstract][Full Text] [Related]
4. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
7. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
[TBL] [Abstract][Full Text] [Related]
8. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.
Peters I; Eggers H; Atschekzei F; Hennenlotter J; Waalkes S; Tränkenschuh W; Grosshennig A; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
BJU Int; 2012 Jul; 110(2 Pt 2):E144-52. PubMed ID: 22289415
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma.
Li P; Liu J; Li J; Liu P
Mol Biol Rep; 2019 Aug; 46(4):4377-4383. PubMed ID: 31147860
[TBL] [Abstract][Full Text] [Related]
10. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
Lin YL; Xie PG; Wang L; Ma JG
Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
[TBL] [Abstract][Full Text] [Related]
12. Hypermethylation of the 16q23.1 tumor suppressor gene ADAMTS18 in clear cell renal cell carcinoma.
Xu B; Zhang L; Luo C; Qi Y; Cui Y; Ying JM; Zhang Q; Jin J
Int J Mol Sci; 2015 Jan; 16(1):1051-65. PubMed ID: 25569086
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
14. Nucleobindin 2 expression is an independent prognostic factor for clear cell renal cell carcinoma.
Qi C; Ma H; Zhang HT; Gao JD; Xu Y
Histopathology; 2015 Apr; 66(5):650-7. PubMed ID: 25322808
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
[TBL] [Abstract][Full Text] [Related]
16. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
[TBL] [Abstract][Full Text] [Related]
17. A Four-Gene Promoter Methylation Marker Panel Consisting of
van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
[No Abstract] [Full Text] [Related]
18. Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study.
Koudonas A; Papaioannou M; Kampantais S; Anastasiadis A; Hatzimouratidis K; Dimitriadis G
Medicine (Baltimore); 2022 Jul; 101(28):e29599. PubMed ID: 35838992
[TBL] [Abstract][Full Text] [Related]
19. Golgi Alpha-Mannosidase II as a Novel Biomarker Predicts Prognosis in Clear Cell Renal Cell Carcinoma.
Li C; Guo L; Chen F; Yu W; Rao T; Ruan Y
Oncol Res Treat; 2020; 43(6):264-275. PubMed ID: 32403105
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
Du P; Ye L; Yang Y; Jiang WG
Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
